{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-137754","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.973273+00:00","generated_at":"2026-06-02T01:19:58.150013+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IO Biotech Q1 2024 net loss $19.5M; Phase 3 melanoma interim ORR data expected Q3 2024","bullets":["Net loss $19.5M for Q1 2024 vs $17.0M in Q1 2023; R&D expenses $14.3M (up from $11.9M).","Cash and cash equivalents $118.0M at March 31, 2024; cash runway expected into Q4 2025.","Phase 3 trial (IOB-013) of IO102-IO103 in advanced melanoma: interim ORR analysis expected Q3 2024; PFS analysis projected H1 2025.","Completed Phase 2 basket trial (IOB-022) enrollment; Phase 2 basket trial (IOB-032) expanded with randomized melanoma cohort.","Appointed Faiçal Miyara as Chief Business Officer and Marjan Shamsaei as SVP Commercial & Portfolio Lead."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-137754","json":"https://secwatch.observer/filing/0001193125-24-137754.json","markdown":"https://secwatch.observer/filing/0001193125-24-137754.md","text":"https://secwatch.observer/filing/0001193125-24-137754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/0001193125-24-137754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/d799934d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:19:58.150013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c41c8220c82eeca614afd13bb42a8731bc218701","claim":"IO Biotech, Inc. reported the first quarter ended March 31, 2024 results: net income $19.5 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2024, was $19.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524137754/0001193125-24-137754-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$19.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}